The BET bromodomain inhibitor JQ1 activates HIV latency through antagonizing Brd4 inhibition of Tat-transactivation.
Nucleic Acids Res. 2012; Oct 18:Advance Access
Cheng-Ming Chiang
03 Nov 2012
|
Confirmation, New Finding, Novel Drug Target
This paper elegantly demonstrates the involvement of bromodomain-containing protein 4 (Brd4) in inhibiting HIV-1 gene expression of integrated provirus found in T cells and HeLa-derived HIV latency models, and, accordingly, suppression of Brd4 activity by knockdown or chemical inhibitors, such as JQ1 and I-BET, leads to reactivation...
INDIVIDUAL SUBSCRIPTIONS
Get instant access to Article Recommendations from more than 5,000 expert scientists and clinical researchers, assisted by 5,000 associates, by taking out a monthly subscription. The first month of your subscription will be free of charge.
Start your personal subscription today.
Subscribe for $9.95/monthINSTITUTIONAL SUBSCRIPTIONS
Send a recommendation to your institution's librarian or information manager to request an extended free trial for all users.
Recommend to your LibrarianIf you are a librarian or information manager, you may request an extended free trial for your academic or corporate institution.
Request an Institutional Trialyour institution might be eligible for free access via our sponsorship scheme. Check our sponsorship page.
If you think you should be able to access this content, please contact us.